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419Transcatheter aortic valve replacement (TAVR) has shown
both safety and efﬁcacy (1) beyond 2 years (2,3). Malposi-
tioning can result in transcatheter valve embolization (TVE)
or valve failure. The latter can be treated conservatively, but
poor clinical outcomes have been consistently observed with
this approach (3,4). Transcatheter valve-in-valve (TV-
in-TV) is an established technique to treat acute failure of
TAVR (5,6) (it also has an important potential role in treating
late TAVR failures, likely an issue in the future). Limited data
exist for both TVE and TV-in-TV predictors and sequelae,
with a notable absence of adjudicated and core laboratory
assessments of clinical and hemodynamic outcome. Using
core laboratory adjudicated data, this study sought to inves-
tigate the nature, determinants, and outcomes of 2 clinical
scenarios in which multiple transcatheter valves may be
implanted: TAVR failure with TV-in-TV and TVE.THV = transcatheter heart
valve
TIA = transient ischemic
attack
TV = transcatheter
prosthetic valve
TVE = transcatheter valve
embolization
TV-in-TV = transcatheter
prosthetic valve within
a transcatheter prosthetic
valve
V-in-V = transcatheter
valve-in-surgical valveMethods
Study design and procedure. In an as-treated (AT) anal-
ysis, patients undergoing TAVR in the PARTNER (Place-
ment of AoRTic TraNscathetER Valve) Trial, including
patients randomized in cohort A (those with high surgical
risk), and B (those with inoperable conditions), and accom-
panying nonrandomized registries were studied. All patients
underwent TAVR with the Edwards Sapien heart valve
system (Edwards Lifesciences, LLC, Irvine, California). This
valve was available in 2 sizes, 23 mm and 26 mm. The
procedure was performed with guidance by transesophageal
echocardiography (TEE) and ﬂuoroscopy, as previously
described (1).
Data were dichotomized for those with and without device
embolization. Device embolization was deﬁned as occurring
when the “valve prosthesis moves during or after deployment
such that it loses contact with the aortic annulus,” as proposed
by updated Valve Academic Research Consortium guidelines
(7). In addition, TV-in-TV cases were compared to those
that received a single TAVR in the annular position. A
second valve was implanted at the discretion of the operator in
a similar fashion to and within the ﬁrst valve. The valve size
used was the same as the ﬁrst one in all cases.***Washington Hospital Center, Washington, DC; and the yyySt. Paul’s Hospital,
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diographic characteristics and cli-
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studied. Nonrandomized patients
had the same data collection and
core laboratory analysis as ran-
domized patients. Additional in-
formation on indication, timing,
severity, and mechanism of each
respective complication and im-
mediate outcomes was studied
primarily by using a detailed re-
view of procedure reports, with
review of supplemental informa-
tion from the intraprocedural
TEE and angiograms for clariﬁ-
cation, if required. A minority
of patients had baseline cardiac
computed tomography (CT) scans
available that were systematically
analyzed (8).
Outcomes. Clinical outcomes
studied included acute procedural
and 30-day outcomes and late
outcomes up to 1 year. The prin-
cipal end points compared were
all-cause mortality, cardiovascular
mortality, rehospitalization, stroke,
and New York Heart Association
(NYHA) functional class. Core laboratory echocardiographic
data included valve areas, transvalvular gradients, left ven-
tricular (LV) size and function, and valvular and paravalvular
aortic regurgitation (AR), evaluated with baseline and follow-
up transthoracic echocardiograms (TTEs).
Statistical analysis. Categorical variables were compared
with the Fisher exact test. The Kolmogorov-Smirnov test
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420constructed on the basis of all available follow-up data with
the use of Kaplan-Meier estimates and were compared using
the log-rank test. For multivariable analyses, endpoints
studied included death and cardiovascular death with can-
didate covariates for each outcome, those related to TV-
in-TV or TVE to a signiﬁcance level of 0.1. Cox regression
models using stepwise selection was performed for a 1-year
time point. To study changes in bioprosthetic gradients
over time, longitudinal data analysis was performed using an
SAS mixed model (SAS Institute, Cary, North Carolina)
with repeated measurements. All statistical analyses were
performed with the use of SAS version 9.2 software.Results
Patients and baseline characteristics. A total of 2,554
patients consecutively treated with TAVR were studied.
The cohort consisted of 519 randomized and 2,035 non-
randomized patients. Of these, 63 (2.47%) patients under-
went TV-in-TV and 26 (1.01%) experienced TVE.
TV-in-TV: nature, timing and underlying reasons. For
TV-in-TV, 56 (88.9%) patients were immediate, 2 were
early (just after surgical closure of the LV apex in transapical
cases), and 5 were later (on post-operative days 1, 3, and 16
and months 2 and 4 post-procedure). Indications for TV-in-
TV (Fig. 1) were signiﬁcant post-TAVR AR in 61 cases
(96.8%), 31 (50.8%) transvalvular cases (3 moderate,
1 moderate-severe, and 27 severe), 22 (36.1%) paravalvular
cases (5 moderate, 2 moderate-severe, and 15 severe), and
8 (13.1%) mixed cases (1 moderate and 7 severe). Two
additional cases were implanted primarily for unstable device
position (1 very high, 1 very low).
In the 61 cases of AR (Fig. 1), 33 were due to leaﬂet
malfunction and 25 were due to malpositioning; 3 were of
unclear causes. For paravalvular AR, 20 of 22 (90.9%) cases
were known to be associated with malpositioning (14 were
implanted high, and 6 were implanted low) versus 2 of 31
(6.4%) cases with transvalvular AR (2 implanted low); for
transvalvular AR, the predominant stipulated mechanism
was leaﬂet malfunction in 29 of 31 (93.6%) cases. In the 33
overall cases of leaﬂet malfunction associated with either
transvalvular or mixed AR, the putative causes by narrative
and data review were not stated or were unclear in 31%,
but in many cases there was an identiﬁed cause (Fig. 1).
Causes included calcium impingement, leaﬂet overhang,
post-dilation (disrupting the architecture of the bio-
prosthesis), hypotension starting prior to TAVR (with
inadequate aortic pressure to close the leaﬂets of the
deployed Sapien valve) and a tilted/canted valve.
Baseline clinical variables associated with TV-in-TV
(Table 1) included male sex, higher body surface area
(BSA), prior myocardial infarction (MI), prior coronary
artery bypass graft (CABG), cardiomyopathy and major
arrhythmia (predominantly driven by atrial ﬁbrillation).
Baseline echocardiographic variables associated with TV-in-
TV included larger sinotubular junction diameter, loweraortic valve peak velocity, lower LV ejection fraction, larger
LV end diastolic volume, and moderate or greater mitral
regurgitation (Table 2). The independent predictors of
TV-in-TV were male sex (odds ratio [OR]: 2.64, 95%
CI: 1.31 to 5.30, p ¼ 0.0063), prior CABG (OR: 2.08, 95%
CI: 1.16 to 3.75, p ¼ 0014), and lower baseline LV ejection
fraction (per 10% reduction, OR: 1.03, 95% CI: 1.02 to
1.05, p ¼ 0.0003).
Early and late outcomes of TV-in-TV. During the TAVR
procedure for TV-in-TV cases, there was a greater need for
hemodynamic support, higher volume of contrast used,
higher radiation exposure, and longer procedure and ﬂuo-
roscopy times (Table 3). There were higher levels of creatine
kinase (CK) but not creatine kinase-myocardial band
(CK-MB) or troponin with TV-in-TV (Table 3), suggesting
greater non-cardiac muscle ischemia with TV-in-TV.
At 30 days, all-cause mortality (9.6% vs. 5.9%), cardio-
vascular mortality (8.0% vs. 4.2%), and rehospitalization
(9.8% vs. 5.8%) were higher with TV-in-TV versus no TV-
in-TV respectively, but these differences were not statisti-
cally signiﬁcant (Table 3). Occurrence of stroke, renal
failure, vascular complication or need for open aortic valve
replacement was similar. There was, however, a greater need
for a new pacemaker with TV-in-TV versus no TV-in-TV
(at 30 days, the new pacemaker rate was 11.2% vs. 5.4%,
p ¼ 0.05). Of patients with electrocardiographic data, there
was more abnormal conduction after TV-in-TV versus not
and more left bundle branch block (LBBB); at discharge/
7 days LBBB occurred in 48.5% with TV-in-TV versus
33.8% of those who did not require TV-in-TV, p ¼ 0.08),
despite no signiﬁcant differences at baseline (Online Table 1).
There were no signiﬁcant differences in aortic valve area
or gradients acutely or at follow-up with TV-in-TV (Fig. 2).
After TV-in-TV, mean aortic valve gradient on discharge
TTE was 10.4  4.5 mm Hg versus 10.7  5.0 mm Hg
with no TV-in-TV (p ¼ 0.70). Only 1 case of TV-in-TV
had a mean gradient 20 mm Hg (1.59%); that case had
moderate paravalvular and mild central AR (severe total AR
by core laboratory assessment) with two 26-mm Sapien
prostheses implanted in an annulus measuring 24 mm by
2-dimensional (2D) TEE. Post-TAVR paravalvular, trans-
valvular, and total AR were similar (Online Table 2). Only 5
(7.9%) patients with TV-in-TV had residual total AR
greater than mild (moderate or severe) on discharge or 7-day
TTE; 1 had central AR, and 4 had paravalvular AR. Of the
4 with paravalvular AR, 3 were undersized on review of
baseline cross-sectional annular area on computed tomog-
raphy (CT) (annulus area > transcatheter heart valve (THV)
area); 1 did not have baseline CT data, but a 23-mm
SAPIEN valve was implanted in a borderline large
annulus measuring 22 mm on 2D TEE.
At 1 year, TV-in-TV patients had higher all-cause
mortality (33.3% vs. 21.0%, p ¼ 0.02), cardiovascular
mortality (24.4% vs. 9.1%, p ¼ 0.0005), and a trend to more
rehospitalization (25.5% vs. 17.7%, p ¼ 0.12), but there
were no signiﬁcant differences in stroke rates (9.3% vs. 4.9%,
Figure 1 Stratiﬁcation of Underlying Causes of TVE and TV-in-TV
(A) TVE. (i) Final location of embolization and (ii) operator-identiﬁed causes. (B) TV-in-TV. (i) Indications for TV-in-TV. (ii) Mechanisms of pre-TV-in-TV aortic regurgitation.
(iii) Putative underlying causes are shown in cases where TV-in-TV was performed for leaﬂet malfunction.
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421p ¼ 0.17) (Fig. 3). NYHA status at follow-up was similar
(Online Fig. 2). TV-in-TV was an independent predictor of
cardiovascular mortality (hazard ratio [HR]: 1.86, 95%
conﬁdence interval [CI]: 1.03 to 3.38, p ¼ 0.041) but was
not signiﬁcantly associated with intermediate term all-cause
mortality (HR: 1.43, 95% CI: 0.88 to 2.33, p ¼ 0.15)
(Online Table 3). A landmark analysis showed a more
substantial difference in cardiovascular mortality betweenTV-in-TV and no TV-in-TV groups beyond 30 days than
within the ﬁrst 30 days postprocedure (Fig. 4).
TVE: nature, timing, and underlying reasons. TVE
occurred in 20 patients (76.9%) immediately after valve
deployment, in 5 (19.2%) early (within an hour of implan-
tation but not immediate) and in 1 (3.8%) late (7 hours
postprocedure and related to cardiopulmonary resuscitation).
Although the majority of TVE cases (16 of 26 [61.5%])
Table 1 Baseline Clinical Variables Associated With TV-in-TV and TVE
All Patients
(n ¼ 2,554)
TV-in-TV
(n ¼ 63)
No TV-in-TV
(n ¼ 2,491) p Value
TVE
(n ¼ 26)
No TVE
(n ¼ 2,528) p Value
Age, yrs 84.46  7.17 (2,536) 83.24  6.30 (63) 84.49  7.19 (2,473) 0.058 81.32  8.21 (26) 84.49  7.16 (2,510) 0.04
Male 52.4% (1,337/2,552) 81.0% (51/63) 51.6% (1,285/2,489) <0.0001 76.9% (20/26) 52.1% (1,317/2,526) 0.53
BSA 1.80  0.25 (2,543) 1.89  0.26 (63) 1.80  0.25 (2,480) 0.01 1.92  0.22 (26) 1.80  0.25 (2,517) 0.006
STS score 11.49  4.28 (2,545) 11.43  4.54 (63) 11.49  4.27 (2,482) 0.38 10.32  3.49 (26) 11.50  4.28 (2,519) 0.20
Logistic EuroScore 26.49  16.21 (2,470) 30.19  20.54 (59) 26.40  16.09 (2,411) 0.35 26.66  15.16 (26) 26.49  16.23 (2,444) 0.85
CAD 77.8% (1,984/2,551) 85.7% (54/63) 77.5% (1,929/2,488) 0.12 76.9% (20/26) 77.8% (1,964/2,525) 0.92
Prior MI 26.0% (661/2,538) 44.4% (28/63) 25.5% (632/2,475) 0.0007 38.5% (10/26) 25.9% (651/2,512) 0.15
Prior PCI 39.8% (1,015/2,548) 39.7% (25/63) 39.8% (989/2,485) 0.99 50.0% (13/26) 39.7% (1,002/2,522) 0.29
Prior CABG 42.7% (1,089/2,551) 66.7% (42/63) 42.0% (1,046/2,488) <0.0001 57.7% (15/26) 42.5% (1,074/2,525) 0.12
Cerebrovascular disease 26.3% (657/2,501) 37.1% (23/62) 26.0% (634/2,439) 0.05 20.0% (5/25) 26.3% (652/2,476) 0.47
Peripheral vascular disease 42.8% (1,079/2,522) 52.4% (33/63) 42.5% (1,046/2,459) 0.12 50.0% (13/26) 42.7% (1,066/2,496) 0.45
Porcelain aorta 4.0% (102/2,533) 3.2% (2/63) 4.0% (100/2,470) 1.00 4.0% (1/25) 4.0% (101/2,508) 1.00
Prior BAV 23.4% (594/2,540) 30.2% (19/63) 23.2% (574/2,477) 0.20 26.9% (7/26) 23.3% (587/2,514) 0.67
Pulmonary hypertension 39.0% (943/2,421) 42.9% (27/63) 38.9% (917/2,358) 0.52 33.3% (8/24) 39.0% (935/2,397) 0.57
Permanent pacemaker 21.4% (547/2,551) 27.4% (17/62) 21.3% (530/2,489) 0.25 26.9% (7/26) 21.4% (540/2,525) 0.49
Renal disease (CR 2) 16.6% (423/2,550) 12.7% (8/63) 16.7% (415/2,487) 0.40 7.7% (2/26) 16.7% (421/2,524) 0.29
COPD 43.4% (1,108/2,554) 39.7% (25/63) 43.5% (1,084/2,491) 0.54 53.8% (14/26) 43.3% (1,094/2,528) 0.28
Chest wall radiation 2.6% (67/2,533) 1.6% (1/63) 2.7% (66/2,470) 1.00 8.0% (2/25) 2.6% (65/2,508) 0.14
Chest wall deformities 1.9% (49/2,533) 1.6% (1/63) 1.9% (48/2,470) 1.00 4.0% (1/25) 1.9% (48/2,508) 0.39
Frailty 12.4% (299/2,419) 11.1% (7/63) 12.4% (292/2,356) 0.76 0.0% (0/24) 12.5% (299/2,395)
Values are mean  SD (N) or % (n/N).
BAV ¼ balloon aortic valvuloplasty; BSA ¼ body surface area; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; STS ¼ Society of
Thoracic Surgeons; TVE ¼ transcatheter valve embolization; TV-in-TV ¼ transcatheter prosthetic valve within a transcatheter prosthetic valve.
M
akkar
et
al.
JACC
Vol.62,No.5,2013
M
ultiple
TAVI
in
the
U.S.PARTNER
Trial
July30,2013:418–30
422
Table 2 Baseline Echocardiographic Variables Associated With TV-in-TV and TVE
All
(n ¼ 2,554)
TV-in-TV
(n ¼ 63)
No TV-in-TV
(n ¼ 2,491) p Value
TVE
(n ¼ 26)
No TVE
(n ¼ 2,528) p Value
TTE AV annulus diameter (cm) 1.91  0.27 (1,939) 2.01  0.33 (44) 1.91  0.27 (1,895) 0.10 2.07  0.19 (18) 1.91  0.27 (1,921) 0.004
TTE AV annulus diameter/valve size deployed (mm) 0.78  0.10 (1,902) 0.80  0.14 (44) 0.78  0.10 (1,858) 0.30 0.083  0.009 (18) 0.078  0.011 (1,884) 0.06
TEE AV annulus diameter (cm) 21.44  1.87 (2,548) 21.94  1.79 (63) 21.43  1.87 (2,485) 0.03 21.96  1.84 (26) 21.44  1.87 (2,522) 0.10
TEE AV annulus diameter (mm)/valve size deployed (mm) 0.88  0.06 (2,500) 0.89  0.06 (63) 0.88  0.06 (2,437) 0.04 0.88  0.06 (26) 0.88  0.06 (2,474) 0.42
Sinotubular junction diameter (cm) 2.35  0.38 (1,669) 2.51  0.41 (42) 2.35  0.38 (1,627) 0.007 2.62  0.28 (14) 2.35  0.38 (1,655) 0.003
Aortic root diameter (cm) 3.12  0.41 (2,143) 3.38  0.46 (51) 3.11  0.40 (2,092) <0.0001 3.34  0.22 (18) 3.12  0.41 (2,125) 0.003
AV peak velocity (cm/s) 416.15  64.64 (2,408) 395.30  73.93 (59) 416.67  64.32 (2,349) 0.01 397.14  52.22 (24) 416.29  64.70 (2,384) 0.11
AV mean gradient (mm Hg) 43.83  14.31 (2,424) 40.26  16.08 (59) 43.92  14.26 (2,365) 0.02 39.40  10.22 (24) 43.86  14.33 (2,400) 0.11
AV area (EOA) (cm2) 0.65  0.19 (2,384) 0.67  0.24 (57) 0.65  0.19 (2,327) 0.80 0.72  0.18 (21) 0.65  0.19 (2,363) 0.08
LVED volume (ml) 132.56  49.82 (1,181) 176.39  59.36 (28) 131.49  49.11 (1,153) <0.0001 152.60  92.08 (10) 132.38  49.34 (1,171) 0.77
LVES volume (ml) 66.89  41.06 (1,181) 105.85  53.06 (28) 65.95  40.29 (1,153) <0.0001 86.96  83.39 (10) 66.72  40.54 (1,171) 0.66
LV ejection fraction 52.50  12.94 (2,444) 44.34  14.02 (60) 52.70  12.85 (2,384) <0.0001 51.14  13.25 (24) 52.50  12.94 (2,420) 0.48
% of patients with mitral regurgitation 0.72 0.49
None (n) 3.2% (78/2,427) 3.3% (2/60) 3.2% (76/2,367) 0.0% (0/24) 3.2% (78/2,403)
Trace 24.5% (594/2,427) 20.0% (12/60) 24.6% (582/2,367) 25.0% (6/24) 24.5% (588/2,403)
Mild 50.4% (1,223/2,427) 45.0% (27/60) 50.5% (1,196/2,367) 41.7% (10/24) 50.5% (1,213/2,403)
Moderate 18.9% (458/2,427) 30.0% (18/60) 18.6% (440/2,367) 33.3% (8/24) 18.7% (450/2,403)
Severe 3.0% (74/2,427) 1.7% (1/60) 3.1% (73/2,367) 0.0% (0/24) 3.1% (74/2,403)
Moderate or severe 21.9% (532/2,427) 31.7% (19/60) 21.7% (513/2,367) 0.06 33.3% (8/24) 21.8% (524/2,403) 0.17
% of patients with transvalvular aortic regurgitation 0.91 0.05
None 10.6% (264/2,493) 13.1% (8/61) 10.5% (256/2,432) 20.0% (5/25) 10.5% (258/2,468)
Trace 31.7% (790/2,493) 32.8% (20/61) 31.7% (770/2,432) 12.0% (3/25) 31.9% (787/2,468)
Mild 44.8% (1,118/2,493) 45.9% (28/61) 44.8% (1,090/2,432) 44.0% (11/25) 44.9% (1,108/2,468)
Moderate 9.5% (236/2,493) 6.6% (4/61) 9.5% (232/2,432) 20.0% (5/25) 9.4% (231/2,468)
Severe 0.9% (23/2,493) 0.0% (0/61) 0.9% (23/2,432) 0.0% (0/25) 0.9% (23/2,468)
Moderate or severe 10.7% (259/2,431) 6.7% (4/60) 10.8% (255/2,371) 0.31 20.8% (5/24) 10.6% (254/2,407) 0.17
Values are mean  SD (N) or % (n/N). p values are based on the chi-square test or Fisher exact test, as appropriate, for categorical variables and on Wilcoxon rank sum test for medians for continuous variables.
AV ¼ aortic valve; EOA ¼ effective oriﬁce area; LV ¼ left ventricular; LVED ¼ left ventricular end-diastolic; LVES ¼ left ventricular end-systolic; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography; other abbreviations as in Table 1.
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Table 3 Periprocedural and 30-Day Outcomes Associated With TV-in-TV and TVE
All
(n ¼ 2,554)
TV-in-TV
(n ¼ 63)
No TV-in-TV
(n ¼ 2,491) p Value
TVE
(n ¼ 26)
No TVE
(n ¼ 2,528) p Value
Periprocedural variables
Prior TAVR procedures performed in
treating center
75.26  57.73 81.94  57.72 75.09  57.81 0.35 56.8  45.8 75.4  57.8 0.10
Access approach 0.05
Transfemoral 57.7% (1,474/2,554) 52.4% (33/63) 57.8% (1,441/2,491) 0.39 76.9% (20/26) 57.6% (1,455/2,528)
Transapical 42.3% (1,080/2,554) 47.6% (30/63) 42.2% (1,050/2,491) 0.39 23.1% (6/26) 42.4% (1,073/2,528)
% of patients with valve size shown (mm)
23 mm 52.1% (1,305/2,504) 41.3% (26/63) 52.4% (1,279/2,441) 0.08 34.6% (9/26) 52.3% (1,295/2,478) 0.07
26 mm 47.8% (1,198/2,504) 58.7% (37/63) 47.6% (1,161/2,441) 0.08 65.4% (17/26) 47.7% (1,182/2,478) 0.07
Hemodynamic support (CPB or IABP) 8.0% (203/2,543) 28.6% (18/63) 7.5% (185/2,480) <0.0001 50.0% (13/26) 7.6% (191/2,517) <0.0001
Cardiopulmonary bypass 5.2% (133/2,543) 25.4% (16/63) 4.7% (117/2,480) <0.0001 38.5% (10/26) 4.9% (124/2,517) <0.0001
IABP during procedure 4.2% (108/2,543) 11.1% (7/63) 4.1% (101/2,480) 0.02 19.2% (5/26) 4.1% (104/2,517) <0.0001
Conversion to open heart surgery 1.4% (36/2,542) 1.6% (1/63) 1.4% (35/2,479) 0.60 30.8% (8/26) 1.2% (29/2,516) <0.0001
Volume of contrast media (n with
available data)
123.89  121.21 (2,455) 201.92  382.60 (60) 121.93  106.28 (2,395) 0.0006 222.39  131.66 (23) 122.88  120.72 (2,431) <0.0001
Time in catheter lab or OR (min), (n with
available data)
222.00 [191.00–260.00] (2,545) 267.50 [226.00–338.00] (62) 221.00 [190.00–259.00] (2,483) <0.0001 343.00 [239.00–418.00] (26) 222.00 [190.00–259.00] (2,519) <0.0001
Total procedure time (skin-to-skin) (min) 106.00 [82.00–144.00] (2,531) 143.00 [107.00–210.00] (63) 105.00 [81.00–143.00] (2,468) <0.0001 196.00 [152.00–313.50] (24) 105.00 [81.00–143.00] (2,506) <0.0001
Fluoroscopy total time 18.00 [12.00–26.00] (2,426) 25.00 [18.00–36.00] (61) 17.00 [12.00–25.00] (2,365) <0.0001 35.50 [27.00–63.00] (22) 17.00 [12.00–25.00] (2,403) <0.0001
Radiation exposure (n with
available data)
4,650.03  11,104.52 (1,715) 7,751.15  16,154.78 (47) 4,562.65  10,922.76 (1,668) 0.005 6,411.33  12,475.21 (15) 4,637.22  11,097.25 (1,699) 0.27
Days in hospital post-procedure,
(n with available data)
6.00 [5.00–8.00] (1,593) 7.00 [4.00–9.00] (31) 6.00 [5.00–8.00] (1,562) 0.39 6.00 [4.00–8.00] (10) 6.00 [5.00–8.00] (1,582) 0.87
24 h post-procedure
CK (U/l) 155.00 [68.00–352.00] (1,218) 212.00 [115.00–438.00] (33) 154.00 [68.00–348.00] (1,185) 0.02 353.00 [183.50–1,137.00] (8) 155.00 [68.00–349.00] (1,210) 0.02
Change from 1  ULN at baseline 71.00 [6.00–278.50] (968) 206.00 [26.00–408.00] (25) 69.00 [6.00–275.00] (943) 0.03 248.00 [80.00–1,401.00] (6) 70.50 [6.00–277.00] (962) 0.05
CK-MB (U/l) 7.00 [3.60–17.00] (1,377) 7.00 [3.70–17.40] (31) 7.00 [3.60–17.00] (1,346) 0.55 11.50 [5.40–19.90] (6) 7.00 [3.60–17.00] (1,371) 0.58
Troponin I (ng/ml) 1.32 [0.45–5.44] (1,276) 1.14 [0.52–7.94] (30) 1.33 [0.45–5.39] (1,246) 0.57 2.02 [0.99–6.74] (10) 1.31 [0.45–5.40] (1,265) 0.25
30-day outcomes (KM estimates)
Mortality
All cause 6.0% (154) 9.6% (6) 5.9% (148) 0.27 26.9% (7) 5.8% (147) <0.0001
Cardiovascular 4.3% (109) 8.0% (5) 4.2% (104) 0.16 23.4% (6) 4.1% (103) <0.0001
Repeat hospitalization 5.9% (145) 9.8% (6) 5.8% (139) 0.19 5.0% (1) 5.9% (144) 0.88
Stroke or TIA 3.8% (96) 4.8% (3) 3.8% (93) 0.68 13.2% (3) 3.7% (93) 0.02
Stroke 3.3% (84) 4.8% (3) 3.3% (81) 0.51 9.0% (2) 3.3% (82) 0.15
Death from any cause or
major stroke
8.2% (209) 12.8% (8) 8.1% (201) 0.21 26.9% (7) 8.0% (202) 0.0001
Myocardial infarction 0.8% (20) 0.0% (0) 0.8% (20) 0.47 3.8% (1) 0.8% (19) 0.057
Open aortic valve replacement 0.5% (14) 0.0% (0) 0.6% (14) 0.55 26.9% (7) 0.3% (8) <0.0001
Vascular complications 13.1% (333) 9.6% (6) 13.2% (327) 0.39 43.2% (11) 12.8% (322) <0.0001
Bradyarrhythmic event 6.7% (167) 12.8% (8) 6.5% (159) 0.05 4.2% (1) 6.7% (166) 0.69
Permanent pacemaker 5.6% (140) 11.2% (7) 5.4% (133) 0.05 4.2% (1) 5.6% (139) 0.82
Renal failure (dialysis required) 2.9% (72) 3.2% (2) 2.9% (70) 0.89 17.4% (4) 2.8% (68) <0.0001
Dialysis lasting >30 days 0.6% (15) 0.0% (0) 0.6% (15) 0.53 0.0% (0) 0.6% (15) 0.72
Values are mean  SD, % (n/N), mean  SD (N), median (interquartile range) (N), or % (n). p values are based on the chi-square or Fisher exact test, as appropriate, for categorical variables and on the Wilcoxon rank sum test for medians for continuous variables. For KM
estimates, p values are from the log rank test.
CPB ¼ cardiopulmonary bypass; CK ¼ creatine kinase; CKMB ¼ creatine kinase-myocardial band; IABP ¼ intra-aortic balloon pump; IQR ¼ interquartile range; KM ¼ Kaplan-Meier; OR ¼ operating room; TIA ¼ transient ischemic attack; ULN ¼ upper limit of normal; other
abbreviations are shown in Table 1.
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Figure 2
TV-in-TV and Bioprosthetic Hemodynamics by
Echocardiography
(A) Aortic valve areas at multiple time points stratiﬁed by TV-in-TV (p ¼ 0.15 in the
longitudinal mixed model for the slope of TV-in-TV vs. no TV-in-TV). (B) Peak (p ¼
0.23 in the longitudinal mixed model for the slope of TV-in-TV vs. no TV-in-TV) and
mean (p ¼ 0.24 in the longitudinal mixed model for the slope of TV-in-TV vs. no
TV-in-TV) gradients at multiple time points stratiﬁed by TV-in-TV.
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425did have multiple transcatheter valve implants (Online
Fig. 1), surgical aortic valve replacement was performed
in 8 patients, and in 2 needed no further intervention.
There was some overlap in the populations studied in those
2 cases of TVE rectiﬁed by TV-in-TV: 1 patient had the
ﬁrst TAVR positioned in the left ventricular outﬂow tract
(LVOT), and a second was implanted in an overlapping
fashion at the annular level, and in the other case, the ﬁrst
TAVR was positioned low, a second high, and a third
between the 2 at the annular level, overlapping with and
stabilizing the 2 previous devices. In one case of TVE,
movement into the left ventricle was caused by an attempt
at TV-in-TV for initial TAVR failure.
Initial direction of embolization was aortic (above the
aortic annulus) in 13 patients (50%) and ventricular (below
the aortic annulus) in 13 patients (50%); in 1 patient,
although the initial direction of embolization was ventric-
ular, the operators were able to pull the valve to an aortic
location by inﬂating a balloon within it (Online Fig. 1,
Online Table 4). Of the 26 cases of embolization, 14
(53.8%) were managed percutaneously, and 12 (46.2%)required conversion to open heart surgery. There were more
valve embolizations in procedures performed by the trans-
femoral (TF) approach: 20 of 1,455 (1.37%) TF cases and 6
of 1,073 (0.58%) transapical (TA) cases resulting in
embolization (p ¼ 0.05). Despite this, a smaller proportion
of TF cases had a ﬁnal ventricular position, with 7 of 20
(35.0%) of the embolizations ventricular in those treated by
the TF approach versus 5 of 6 (83.3%) by the TA approach
(p ¼ 0.065).
Patients with valve embolization had a higher BSA and
were more likely to be males (Table 1). Patients with valve
embolization also had on average larger aortic annuli by 2D
TTE and a trend toward lower mean aortic valve gradients
at baseline (Table 2).
A cause for embolization was deﬁned in post-procedural
operator reports in 73% of cases (Fig. 1). The most com-
monly stated causes were malpositioning (19%), annulus/
aortic valvular complex anatomy (15%, an undersized pros-
thesis, an angulated aorta, sinus/commissural asymmetry and
heavily calciﬁed and bulky leaﬂets), and pacing failure (11%).
A valve was considered malpositioned when an operator
stated in the procedural report that the initial positioning of
the prosthesis prior to deployment was either too high or too
low. Other stated causes of embolization included post-
cardiopulmonary resuscitation, postdilation, cardiac manip-
ulation, displacement during attempted transcatheter
valve-in-valve, poor ﬂuoroscopic angle for implantation, and
incomplete/delayed device balloon inﬂation (Fig. 1). There
was a trend to fewer prior TAVR procedures performed in
the treating center for patients with embolized valves, 56.8
 45.8 in patients with embolized valves versus 75.4  57.8
in patients without embolized valves, indicating there was
a tendency for TVE to diminish with a center’s increasing
experience. An analysis of the relative contribution of the
ﬁrst 20 cases of a center’s experience to embolization by
approach revealed that 5 of 20 cases of embolization (25%)
occurred with the TF approach during centers’ ﬁrst 20 cases,
whereas 5 of 6 cases (83%) of embolization occurred with
the TA approach during centers’ ﬁrst 20 cases.
A large proportion of cases had no stated cause of
embolization (7 of 26, 27%). A retrospective review of
available baseline contrast-enhanced CT scans or procedural
ﬂuoroscopy or TEE data revealed important technical/
anatomical contributory causes of TVE in the form of
incorrect crimping of the TAVR device on the delivery
system, device undersizing, a small sinotubular junction with
ventricular embolization, and marked paucity of aortic valve
calciﬁcation (Online Appendix).
Early and late outcomes of TVE. Patients with embolized
valves were much more likely to require hemodynamic
support (Table 3). There was a signiﬁcantly higher rate of
conversion to open heart surgery and use of contrast and
ﬂuoroscopy, and procedure times were signiﬁcantly increased
by embolization. TVE had a greater 30-day mortality when it
occurred with the TA versus the TF approach and when the
ﬁnal TAVR position was ventricular versus aortic (p ¼ NS
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Figure 3 Late Outcomes With TV-in-TV
Outcomes stratiﬁed by TV-in-TV including (A) all-cause mortality; (B) cardiovascular mortality; (C) rehospitalization; and (D) stroke.
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426for both) (Online Fig. 3). Similarly, conversion to surgery
carried a 30-day mortality of 33.3% (4 of 12 patients)
compared to 14.3% (2 of 14 patients) in those managed
percutaneously (1 of whom did not receive a transcatheter
valve and died 6 days post-procedure); (p ¼ 0.36).
At 30 days, death, cardiac death, and stroke were signiﬁ-
cantly greater with embolization. Major bleeding, major
vascular complications, and requirement for open aortic valve
replacement were also substantially increased. There was
a greater frequency of neurological events (stroke and/or
transient ischemic attack [TIA]) with TVE at 30 days (13.2%
vs. 3.7%, p ¼ 0.02) but the differences were driven by only
3 cases of stroke/TIA: 1 major and 1 minor stroke and 1 case
of TIA. TVE was not a signiﬁcant predictor of stroke (HR:
2.67, 95% CI: 0.66 to 10.85, p ¼ 0.15).
Although predominantly driven by early event rates, late
adverse outcomes remained signiﬁcantly higher with
embolization (Table 4, Fig. 5). At 1 year, embolization
remained a signiﬁcant independent predictor of mortality
(HR: 2.68, 95% CI: 1.34 to 5.36, p ¼ 0.0055) (OnlineTable 3). In a landmark analysis, patients with emboliza-
tion seemed to carry an incremental risk of late all-cause
mortality but not cardiovascular mortality (Fig. 4).
Discussion
The most important ﬁndings from this study are that both
TV-in-TV and TVE carry a heavy burden of complications
and that all cases had probable underlying causes, either
stated by the operator or apparent from a retrospective
review of the data; these causes were either anatomical or
technical, and many could be considered preventable
through appropriate procedural planning.
TV-in-TV was performed in 2.47% of cases, mostly as
a “rescue” for moderate or more valvular or paravalvular AR.
TV-in-TV avoided emergency surgery for failed TAVR in
98.4% (62 of 63) of cases. Rescue TV-in-TV was associated
with longer procedure times, more frequent requirement for
hemodynamic support, increased radiation exposure and
contrast use, larger total CK enzyme leakage, and longer
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Figure 4 Landmark Analysis of the Effect of TV-in-TV and TVE on Mortality
Kaplan-Meier plot is shown with the start date for analysis reset at 30 days. (A) Effect of TV-in-TV in mortality; (B) effect of TVE on mortality. (i) All-cause mortality.
(ii) Cardiovascular mortality.
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427hospital stays. TV-in-TV was also associated with a higher
incidence of cardiac conduction abnormalities and perma-
nent pacemaker implantation.
TVE occurred in 1.01% of patients and in most cases was
immediate and managed percutaneously with a further
TAVR positioned at the aortic annulus. TVE resulted in
signiﬁcantly higher rates of hemodynamic support and
conversion to open heart surgery and use of contrast and
ﬂuoroscopy, and procedure times were also signiﬁcantly
increased. There appeared to be trends toward worse
outcomes with TVE occurring in TF versus TA procedures
and in ventricular versus aortic TVE. In multivariable
analyses, TVE and TV-in-TV were independent predictors
of 1-year all-cause and cardiovascular mortality, respectively.
TV-in-TV in context. After TV-in-TV, only 5 of 63
(7.9%) patients had signiﬁcant postprocedural AR, similar to
that in the larger TAVR population without TV-in-TV.In contrast to prior series of balloon-expandable (5) and
self-expanding TV-in-TV (6), in whom malpositioning-
related paravalvular AR was the predominant cause of
post-TAVR AR, we saw a high frequency of transvalvular
regurgitation (49.2%). Online Table 5 summarizes the
ﬁndings of the three studies evaluating TV-in-TV.
The differences are probably due to the structure of the
valves used. The prior balloon-expandable series used the
SAPIEN XT valve (5), whose leaﬂets are in a partially closed
conﬁguration even when open. Our series used exclusively an
earlier device iteration, the Edwards-SAPIEN valve, whose
leaﬂets have a default open conﬁguration. This is thought to
have a greater likelihood of the native leaﬂets outside the
deployed TAVR frame overhanging the prosthesis and
making contact with the new prosthetic leaﬂets, causing them
to “freeze” or “stick” (5). This hypothesis is supported by
the recently reported data from the PARTNER 2B trial (9),
Table 4 Kaplan-Meier Outcomes for TV-in-TV and TVE at 1 Year
Outcome
All
(n ¼ 2,554)
TV-in-TV
(n ¼ 63)
No TV-in-TV
(n ¼ 2,491) p Value
TVE
(n ¼ 26)
No TVE
(n ¼ 2,528) p Value
Death from any cause 21.3% (514) 33.3% (19) 21.0% (495) 0.02 50.5% (13) 21.0% (502) <0.0001
Death from cardiovascular cause 9.5% (224) 24.4% (13) 9.1% (211) 0.0005 27.9% (7) 9.3% (217) 0.0002
Repeat hospitalization* 17.9% (396) 25.5% (13) 17.7% (383) 0.12 21.2% (4) 17.9% (393) 0.62
Death from any cause or repeat hospitalization 32.5% (792) 48.9% (29) 32.1% (763) 0.004 54.2% (14) 32.3% (779) 0.002
Stroke or TIA 6.2% (144) 9.3% (5) 6.1% (139) 0.37 13.2% (3) 6.1% (141) 0.10
TIA 1.2% (27) 0.0% (0) 1.2% (27) 0.43 4.2% (1) 1.2% (26) 0.10
Stroke 5.0% (117) 9.3% (5) 4.9% (112) 0.17 9.0% (2) 4.9% (115) 0.33
Minor 4.1% (96) 7.7% (4) 4.0% (92) 0.25 4.2% (1) 4.1% (95) 0.87
Major 0.9% (21) 1.6% (1) 0.9% (20) 0.47 4.8% (1) 0.9% (20) 0.057
Death from any cause or major stroke 23.0% (559) 34.6% (20) 22.8% (539) 0.03 50.5% (13) 22.8% (547) 0.0002
Myocardial infarction 1.5% (34) 1.8% (1) 1.5% (33) 0.82 3.8% (1) 1.4% (33) 0.19
Values are % (n). *Due to aortic stenosis or complications of the valve procedure.
Abbreviations are shown in Tables 1 and 3.
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428where TV-in-TV occurred in 3.7% of SAPIEN cases
compared to 1.1% cases with SAPIEN XT implants
(p ¼ 0.05). (Similarly, the self-expanding CoreValve [Med-
tronic, Inc.,Minneapolis,Minnesota] device consists of a longD
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429We saw male sex to be the most important independent
predictor of TV-in-TV. Device undersizing by echocardi-
ography did not appear to account for this, with no differ-
ence in the annular dimension:valve size ratio (Table 2).
There were limited baseline CT data available, and it is
known that relative undersizing by cross-sectional measures
is relatively more substantial in males than in females (10).
The number of prior TAVR procedures performed in the
treating center, a measure of each center’s clinical experience
in TAVR, did not differ for TV-in-TV cases (Table 2),
suggesting that the learning curve for the TAVR procedure
did not contribute to this complication. There may be a lower
threshold for TV-in-TVwith greater operator experience that
counteracts any reduction in the need for the maneuver.
Valvular function and implications for late TV-in-TV.
The former study of balloon-expandable TV-in-TV showed
no statistically signiﬁcant differences in TAVR valve
gradients acutely (5). In contrast, the investigators found
a later statistically signiﬁcant but clinically insigniﬁcant
difference in gradients at 1 year (15  4 mm Hg vs. 11 
4 mm Hg, p ¼ 0.02) that we did not. The Italian registry
reported no difference in gradients at follow-up after TV-in-
TV with the CoreValve self-expanding TAVR (6).
All TV-in-TV studies (Online Table 5) concur on the
similarities in gradients after TV-in-TV, which appear lower
than that seen after transcatheter valve-in-surgical valve
(V-in-V) for degenerated bioprostheses, where mean gra-
dients 20 mm Hg have been seen in 40% of cases with
balloon-expandable TAVR (11). We saw a mean gradient
of 20 mm Hg in only 1 patient (1.6%). This may be
because, in contrast to V-in-V, performed in surgical (mostly
stented) bioprostheses, the landing zone in TV-in-TV is
a more compliant metal frame; in view of this, forceful
expansion of a second transcatheter valve is conceivably
strong enough to achieve potentially similar intraluminal
dimensions. This may also have relevance to the changes
seen in cardiac conduction.
Impact of TV-in-TV on survival and cardiac conduction.
Prior TV-in-TV studies (5,6) were underpowered for de-
ﬁnitive conclusions on outcomes. Despite the absence of
differences in intermediate term valvular function, we found
TV-in-TV to be an independent predictor of cardiovascular
mortality. Although the underlying mechanisms for this
remain unclear, the excess of abnormal conduction and
permanent pacemaker implantation could be important.
Induced LBBB remains an area of controversy. Although
Urena et al. (12) found that new-onset LBBB in 30.2% of 202
patients after balloon-expandable TAVR was not associated
with increased 1-year mortality, a larger multidevice regis-
try of Houthuizen et al. (13) showed an excess mortality
regardless of device deployed. Putative risk mechanisms
associated with LBBB are progression to high-degree atrio-
ventricular conduction disorders and a dyssynchrony-related
reduction in cardiac function.
Of 63 cases of TV-in-TV in the present study, the ﬁrst
valve was malpositioned in 28 cases and implanted low(toward the ventricle) in 10 of these. Low malpositioning is
relatively rare with the balloon-expandable valve but has
been shown to be related to the increased incidence of
LBBB but not permanent pacemaker implantation (12).
Observations from this study have implications for the
future, if late degeneration is observed in TAVR prostheses
and late elective TV-in-TV is considered. Similar gradients
and valvular functions at early and midterm follow-up
suggest that elective TV-in-TV is likely to offer favorable
hemodynamic results. The increased cardiovascular mor-
tality we observed from emergent, acute TV-in-TV cannot
be extrapolated to the late, elective setting. Nevertheless,
until this is better understood, TV-in-TV procedures,
whether performed early or late, demand close cardiological
follow-up.
TVE in context. There has been a considerable variability
among series in the reported incidence of TVE. The SAPIEN
AorticBioprosthesis EuropeanOutcome (SOURCE) registry
reported an incidence of 0.3% (14) whereas the incidence
was 10% in an early pre-US PARTNER experience of the
TA approach (15). We saw a tendency for TVE to diminish
with a center’s increasing experience. This phenomenon
appeared more marked with the TA approach, with 83% of
cases of embolization occurring with the TA approach during
centers’ ﬁrst 20 cases. Interestingly, there were no TVEs in
more than 500 TF implants in the recently presented
PARTNER 2B trial; in all likelihood this was attributable
to increased operator and site experience (9).
There are several important points related to the inter-
action between access approach (TF or TA) and ﬁnal
location of the embolized valve (aortic or ventricular)
(Online Table 6). Although there was a trend toward more
embolizations by the TF approach, the TA approach was
associated with more ventricular embolization and a higher
consequent rate of mortality. Indeed, aortic embolization in
TF cases appeared less dangerous in that the only patient
that died did not receive a TAVR. Accordingly, whether it
is after or before dealing with the embolized valve, TAVR
should be completed. Despite relatively more ventricular
embolizations with the TA approach, the outcome of
ventricular embolization appeared better with this
approach; this may be related to the procedural setup and
the ability to convert to emergent open surgery efﬁciently.
Although TVE was mostly immediate, several cases
occurred some time later, up to 1-h postimplantation. We
saw only 1 case of late embolization at 7 hours post-
procedure in the context of cardiopulmonary resuscitation.
Spontaneous late ventricular embolization has been re-
ported up to 2 days post-procedure, in a case of TV-in-TV
(16); such a phenomenon is likely attributable to device
undersizing.
Although TVE is often related to technical factors such as
timing of balloon inﬂation and suboptimal rapid pacing,
anatomic factors emerged as an equally important cause
of TVE. We saw larger annuli in cases with embolization
(2.04 cm [IQR 1.94 to 2.23 cm] vs. 1.92 cm [IQR 1.73 to
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4302.06 cm], p ¼ 0.004) (Table 2). Despite being identiﬁed by
the operator in only 1 case, undersizing was present in at
least 7 of 26 (26.9%) of cases. Similarly, Tay et al. (17)
described several cases of undersizing by 2D TEE
measurements in their 7 patient series. We also saw device
oversizing to contribute to TVE, with ventricular emboli-
zation in a case with a disproportionately small sinotubular
junction.
Misplacement can clearly contribute to both TVE and
TV-in-TV. In this regard, accurate determination of the
annulus location with a coplanar ﬂuoroscopic projection is
essential.
Study limitations. This was a retrospective analysis of 2
relatively rare complications. As such, information was based
mainly on a review of procedural notes, with a reliance on
the accuracy of center-led reporting. There were limited CT
data available at baseline, restricting comprehensive inter-
pretation. Our ﬁndings were based on the ﬁrst generation of
the balloon-expandable Sapien prosthesis, which may limit
its applicability to the more recent Sapien XT prosthesis.
Conclusions
Acute transcatheter valve failure and TVE can often be
rectiﬁed through the implantation of multiple valves, facil-
itating a successful immediate outcome. Despite this, both
TV-in-TV and TVE predicted adverse outcomes at 1 year.
Considerable effort should therefore be invested in their
avoidance, particularly because they are often caused by
anatomic and technical pitfalls that may be preventable with
judicious procedural planning.
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